Literature DB >> 23599025

Urinary iodine excretion after contrast computed tomography scan: implications for radioactive iodine use.

Grace L Nimmons1, Gerry F Funk, Michael M Graham, Nitin A Pagedar.   

Abstract

IMPORTANCE: Patients who undergo radiographic studies with contrast receive an enormous bolus of iodine. This can delay subsequent use of radioactive iodine (RAI) therapy because the iodine can compete for uptake. There is a paucity of literature on the minimum interval between contrast administration and RAI therapy.
OBJECTIVE: To better characterize how long it takes for the iodine load from an intravenous contrast bolus to clear from the body. DESIGN, SETTING, AND PARTICIPANTS: A prospective cohort of 21 adults undergoing intravenous contrast CT studies at a tertiary academic medical center; exclusion criteria included history of thyroid disease or thyroidectomy, history of renal insufficiency, pregnancy, and other contrast administration within 1 year. INTERVENTION: Morning urine samples were taken before the scan for analysis and then every 2 weeks thereafter for 12 weeks. RESULTS The median baseline iodine level was 135 μg/L (range, 29-1680 μg/L), and median peak level was 552 μg/L (range, 62-6172 μg/L). Median time for urinary iodine level to normalize was 43 days, with 75% of subjects returning to baseline within 60 days, and 90% of subjects within 75 days. Baseline iodine level was a significant predictor of postcontrast iodine levels. Age, sex, weight, and estimated glomerular filtration rate were not significant. CONCLUSIONS AND RELEVANCE: These results may be used for guidance on the timing of RAI use following contrast exposure. The practice at our institution is to wait 2 months and then check a 24-hour urinary iodine level. This alleviates concerns about contrast use in patients with thyroid carcinoma interfering with adjuvant radioiodine therapy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23599025     DOI: 10.1001/jamaoto.2013.2552

Source DB:  PubMed          Journal:  JAMA Otolaryngol Head Neck Surg        ISSN: 2168-6181            Impact factor:   6.223


  7 in total

1.  Percutaneous Coronary Intervention for Chronic Total Occlusion versus Percutaneous Coronary Intervention for Non-Complex Coronary Lesions: Is There a Different Impact on Thyroid Function?

Authors:  Çağın Mustafa Üreyen; Kahraman Coşansu; Mustafa Gökhan Vural; Sait Emir Şahin; Mehmet Akif Çakar; Harun Kılıç; Mustafa Tarık Ağaç; Hüseyin Gündüz; Ramazan Akdemir; Ersan Tatlı
Journal:  Med Princ Pract       Date:  2019-09-20       Impact factor: 1.927

2.  Urinary iodine excretion and serum thyroid function in adults after iodinated contrast administration.

Authors:  Sun Y Lee; Donny L F Chang; Xuemei He; Elizabeth N Pearce; Lewis E Braverman; Angela M Leung
Journal:  Thyroid       Date:  2015-03-23       Impact factor: 6.568

Review 3.  A review: Radiographic iodinated contrast media-induced thyroid dysfunction.

Authors:  Sun Y Lee; Connie M Rhee; Angela M Leung; Lewis E Braverman; Gregory A Brent; Elizabeth N Pearce
Journal:  J Clin Endocrinol Metab       Date:  2014-11-06       Impact factor: 5.958

4.  2021 European Thyroid Association Guidelines for the Management of Iodine-Based Contrast Media-Induced Thyroid Dysfunction.

Authors:  Tomasz Bednarczuk; Thomas H Brix; Wolfgang Schima; Georg Zettinig; George J Kahaly
Journal:  Eur Thyroid J       Date:  2021-06-16

Review 5.  Consequences of excess iodine.

Authors:  Angela M Leung; Lewis E Braverman
Journal:  Nat Rev Endocrinol       Date:  2013-12-17       Impact factor: 43.330

6.  Urinary Iodine Clearance following Iodinated Contrast Administration: A Comparison of Euthyroid and Postthyroidectomy Subjects.

Authors:  Janice D Ho; James F Tsang; Kylie A Scoggan; William D Leslie
Journal:  J Thyroid Res       Date:  2014-11-12

7.  Management of Thyrotoxicosis Induced by PD1 or PD-L1 Blockade.

Authors:  Alessandro Brancatella; Isabella Lupi; Lucia Montanelli; Debora Ricci; Nicola Viola; Daniele Sgrò; Lucia Antonangeli; Chiara Sardella; Sandra Brogioni; Paolo Piaggi; Eleonora Molinaro; Francesca Bianchi; Michele Aragona; Andrea Antonuzzo; Andrea Sbrana; Maurizio Lucchesi; Antonio Chella; Alfredo Falcone; Stefano Del Prato; Rossella Elisei; Claudio Marcocci; Patrizio Caturegli; Ferruccio Santini; Francesco Latrofa
Journal:  J Endocr Soc       Date:  2021-05-15
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.